Abstract 1728P
Background
The prevalence of oncology survivors is increasing exponentially. More than half of them experience difficulty in returning to their pre-disease socio-familial role. Comprehensive Oncology Units are infrequent in our environment. In our center we have implemented this novel Unit in order to improve the quality of life of our cancer survivors during follow-up.
Methods
Prospective quasi-experimental study. From March 2022 to March 2023. A total of 232 patients were included in the Comprehensive Oncology Unit of the Juan Ramón Jiménez Hospital in Huelva. The aim of our study is to describe the psychosocial, nutritional and physical needs of cancer survivors during follow-up and the impact of the intervention on their quality of life.
Results
The median age of the patients was 53 years (33 - 78). Ninety-six percent were women. Ninety percent had been diagnosed with breast cancer, followed by 6 % CRC, 2 % other digestive tumors and 2 % gynecological tumors. 67.1% required assessment for nutrition, 62.9% for rehabilitation, 59.28% for psycho-oncology and 4.8% for social intervention. Of the patients who were evaluated by psycho-oncology, 50% improved their fear of recurrence with only 3 sessions. Regarding nutrition assessment, the median BMI in the population with BMI > 25kg/m2 was 30.7 Kg/m2 at baseline and 29.71 Kg/m2 (22.7 - 40) 6 months after nutrition intervention (p<0.001).
Conclusions
The results of our study reveal that there is a high demand of needs to be covered in cancer survivors beyond the purely clinical aspects that impact on their quality of life. Implementing a Comprehensive Oncology Unit could help to detect these needs and improve their healthy lifestyle habits as well as improve their quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Comprehensive Oncology Unit.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23